Continuing Education Activity

Neuronal brain tumors are a diverse group of primary central nervous system tumors consisting of lesions with either a primarily neuronal background or a mixed glial and neuronal background, termed glioneuronal tumors. These are rare tumors most commonly associated with epilepsy, although other symptoms may also occur, such as headaches, focal neurological deficits, and acute hydrocephalus. This activity reviews the evaluation and treatment of neuronal brain tumors. It highlights the role of the interprofessional team in evaluating and treating patients who are found to harbor these tumors.

Objectives:

• Identify the etiology of neuronal brain tumors.
• Determine the presentation of neuronal brain tumors.
• Assess the evaluation and management of patients with neuronal brain tumors.
• Communicate the importance of interprofessional discussion regarding the evaluation and management of patients with neuronal brain tumors.

Introduction

Neuronal brain tumors are an uncommon group of central nervous system tumors that arise from cells with neuronal differentiation. These tumors may be purely neuronal in origin or have mixed neuronal and glial components, which comprise a subset of glioneuronal tumors.[1] The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors includes 14 distinct tumors within this classification.

The purely neuronal group includes gangliocytoma, multinodular and vacuolating neuronal tumor (MVNT), dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease), central neurocytoma, extraventricular neurocytoma, and cerebellar liponeurocytoma. The mixed glioneuronal group includes ganglioglioma, desmoplastic infantile ganglioglioma/desmoplastic infantile astrocytoma (DIG/DIA), dysembryoplastic neuroepithelial tumor (DNET), diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC), papillary glioneuronal tumor (PGT), rosette-forming glioneuronal tumor (RGNT), myxoid glioneuronal tumor (MGT), and diffuse leptomeningeal glioneuronal tumor (DLGNT). MVNT, DGONC, and MGT are newly classified entities in the WHO CNS tumor classification schema.

Although there are some exceptions, these tumors are mostly low-grade with minimal risk for an aggressive clinical course. They are most commonly present with seizures, although other symptoms of space-occupying intracranial lesions, such as headache, vomiting, papilledema, cerebellar dysfunction, and focal neurological deficit, have also been described.[2][3] Many of these tumors are commonly found in the temporal lobe, which helps explain their predilection for causing seizures.[4] However, these tumors can be found throughout the supratentorial and infratentorial spaces.

Etiology

There is no specific etiology or risk factor related to the development of this diverse group of tumors. However, the current emphasis on molecular characterization of brain tumors provides new insight into the genetic aberrations that underlie their tumorigenesis. Specifically, 2 main molecular subgroups may involve mutations within different cellular regulation pathways. The first subgroup demonstrates mutation in the mitogen-activated protein kinase (MAPK) pathway, which is involved in cellular growth. Specifically, alterations to the proto-oncogene BRAF in the form of BRAF fusion and single nucleotide missense mutations are commonly found in these tumors, with the highest incidence in gangliocytoma and ganglioglioma, with 25% demonstrating fusion mutation and 13-56% demonstrating single nucleotide missense mutation.[5] They have also been described in DLGNT and isolated cases of MVNT.[6][7]

These are gain-of-function mutations that lead to unregulated cell growth. The second group demonstrates mutation in fibroblast growth factor (FGFR) genes, mostly FGFR-1, upstream from the MAPK pathway.[8][9][10] This appears to be especially common in DNETs but has also been identified in neurocytoma and RGNT.[11][12]  Interestingly, these molecular subgroups may help distinguish between tumor types for the glioneuronal group. The BRAF mutation group tends to have a glial component similar to astrocytes, while the FGFR group tends to have a glial component similar to oligodendroglia.

MGTs are newly recognized lesions within the neuronal and glioneuronal tumor groups. They are similar to DNET but have a predilection for location in the septum pellucidum. They are associated with a mutation in the platelet-derived growth factor receptor (PDGFR) gene instead of FGFR.[13][14] This tumor was often previously described as “intraventricular DNET” or “DNET-like neoplasm of the septum pellucidum.”

PGNTs also demonstrate unique genetic aberrations among the neuronal and glioneuronal tumor groups. These often harbor a fusion aberration between solute carrier family 44 choline transporter 1 (SLC44A1) and protein kinase C alpha (PRKCA), creating SLC44A1-PRKCA.[15] Notably, PRKCA is involved in the MAPK signaling pathway.[16] However, these tumors do not have the BRAF mutations that other neuronal and glioneuronal tumors with mutations in the MAPK pathway are found to have.

Dysplastic cerebellar gangliocytoma, also referred to as Lhermitte-Duclos disease, represents a special case within this group of tumors because it is associated with Cowden syndrome, which is also referred to as phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome.[17] PTEN contributes to the mammalian target of the rapamycin (mTOR) pathway, which helps regulate the cell cycle. Wild-type PTEN downregulates the pathway, which reduces proliferation. Mutations in PTEN can lead to unregulated mTOR signaling, which results in tumorigenesis. Common findings in Cowden syndrome include macrocephaly, developmental delay, hemangiomas or other vascular lesions, thyroid hamartomas, breast hamartomas, ganglioneuromas of the kidney, uterine fibroids, various skin lesions including lipomas and keratoses, and dysplastic cerebellar gangliocytoma.

It is important to note that not all tumor samples are found to have the molecular aberrations noted above and that these do not represent all aberrations that have been associated with neuronal and glioneuronal tumors. Other mutations upstream from the signaling pathways noted above may contribute to their development. However, the rare nature of this group of tumors makes their molecular characterization somewhat difficult, with most information gleaned from case reports and small case series. Ongoing efforts are working towards a better understanding of the genetic alterations contributing to their development.

Epidemiology

This is a rare group of brain tumors totaling approximately 0.5 to 2% of all primary CNS tumors.[4] Ganglioglioma and DNET make up the majority of the group. At the same time, descriptions of many newly classified lesions, such as MVNT, DGONC, MGT, and others, are limited to case reports and small case series, likely representing a small portion of all primary CNS tumors. These are primarily tumors of childhood and young adulthood. A diagnosis greater than 30 years old is a rare clinical scenario.

Pathophysiology

Neuronal and glioneuronal tumors are primary CNS tumors arising, at least partially, from mutations in cellular growth pathways, as noted earlier. Due to their rarity, the precise molecular characterization of many of these tumors remains difficult, but ongoing efforts continue to uncover genetic aberrations leading to their development.

Tumor location plays a major role in the pathophysiology of most of these lesions as they are typically WHO 1. Central neurocytoma, extraventricular neurocytoma, and cerebellar liponeurocytoma are WHO grade 2 lesions. The anaplastic form of ganglioglioma represents the group's only WHO grade 3 lesions. Due to their rarity, some newly described tumors, such as DLGNT and MGT, do not yet have a classification. As noted, these tumors can occur anywhere in the supratentorial or infratentorial space, although certain tumors have a predilection for a specific location. For example, dysplastic cerebellar gangliocytoma occurs in the cerebellum, similar to Lhermitte-Duclos disease, in the setting of Cowden syndrome.[17]

However, the most common tumor location appears to be in the temporal lobe, partly because ganglioglioma and DNET are the most common tumor types within this group and have a predilection for this location. These tumors are also found in extra-temporal locations.[18] Location in the temporal lobe and other epileptogenic regions contributes to the development of seizures, which is the most common presenting symptom of this group of tumors.[9][10] Due to this, they are often referred to as long-term epilepsy-associated tumors (LEATs), and their seizures are often refractory to maximal medical therapy.[6][18][19] 

The propensity for these tumors to cause seizures may not only be related to their location since intra-tumoral EEG recordings have demonstrated intrinsic epileptogenic activity in both DNET and ganglioglioma, likely related to their abnormal neuronal cells and structure.[19][20][21][22] Additionally, some studies suggest an upregulation of glutamate receptors (GluR) and downregulation of gamma-aminobutyric acid receptors (GABA-R), which help to create a hyper-excitable state within the tumor.[19][23][24][25][26]

Other symptoms are also related to location. Headache, nausea, vomiting, papilledema, hydrocephalus, cerebellar dysfunction, and focal neurological deficit have also been described. Headache, vomiting, and papilledema are signs of elevated intracranial pressure, which is expected with space-occupying lesions. Since many of these lesions are slow-growing, they may reach large sizes before clinical recognition, with these signs and symptoms being the initial presenting factor that leads to tumor recognition.

Hydrocephalus is mainly secondary to intraventricular or posterior fossa lesions, as tumors in these locations can disrupt the normal cerebrospinal fluid (CSF) outflow pathways. This is usually obstructive-type hydrocephalus, which may be acute if there is a sudden block of normal CSF outflow pathways, as in rare cases of central neurocytoma.[27] Due to its location, Cerebellar dysfunction is common with dysplastic cerebellar gangliocytoma, and other focal neurological deficits are related to individual tumor location within the cerebrum.

Histopathology

The histological features of neuronal and glioneuronal tumors are heterogeneous. All neuronal and glioneuronal tumors should demonstrate positivity for immunohistochemical staining with neuronal cell markers, such as synaptophysin or neuron-specific enolase (NSE).[28][29] However, only the glioneuronal subgroup of tumors should demonstrate positivity for glial differentiation markers in addition to neuronal marker positivity, which is classically seen with glial fibrillary acidic protein (GFAP) positivity. The Ki-67 marker of cellular proliferation is typically low, although higher proliferation rates may be seen for higher-grade tumors such as anaplastic astrocytoma. Cells with oligodendroglia-type cells often demonstrate Olig2 positivity. The major histopathological features of each type of tumor are summarized in Table 1, although details of the immunohistopathological profile of each tumor are not exhaustive in this report.

Table

Table 1: Histological features of individual neuronal and glioneuronal tumors.[30][31].

History and Physical

The findings for an individual patient with a neuronal or glioneuronal brain tumor are variable. A detailed history of the patient’s seizure history should be obtained, including a detailed description of the seizure, whether the patient has previously been evaluated for seizures, and whether there are any family members with a history of seizures. The presence, duration, and severity of other signs and symptoms such as headache, nausea, vomiting, balance difficulties, focal weakness or sensory changes, changes to eyesight, or others should also be obtained. A detailed history of current and previous diagnoses should also be obtained, including current and previous prescription and non-prescription medication.

Next, the practitioner should perform a detailed physical exam focusing on the neurological system. When possible, the examiner must evaluate for mental status changes, visual field deficits, cranial nerve dysfunction, focal neurological deficits, motor or sensory disruptions, cerebellar dysfunction, and papilledema.

For most patients, the physical examination is within normal limits. Rarely, patients may present with acute alteration in mental status and obtundation signifying acute hydrocephalus secondary to CSF outflow obstruction, which may occur with intraventricular tumors such as central neurocytoma or with seizure.

Patients with posterior fossa lesions often demonstrate cerebellar symptoms on examination, such as ataxia, unsteady gait, and a positive Romberg sign, among others. Other focal neurological deficits may include sensory changes or focal weakness, but again, these would be rare due to the indolent nature of most of these lesions and the brain's ability to compensate. Post-ictal patients and those presenting with acute status change secondary to acute hydrocephalus require frequent serial neurological evaluation.

Evaluation

The initial evaluation of a patient suspected of a neuronal or glioneuronal brain tumor requires a detailed history and physical examination, as noted above. Importantly, although rare, patients with acute neurological status changes need an emergent evaluation of the airway status, breathing/oxygenation, and circulatory system (ABCs). This scenario may occur in patients with acute hydrocephalus and may also be true for patients presenting with generalized tonic-clonic or subclinical seizure activity. There should be a low threshold for intubation and resuscitation when a compromise is noted on the initial assessment of the ABCs. However, most patients present with focal partial seizures and signs of increased intracranial pressure, such as headaches. 

CT

Patients presenting with acute deficit should first undergo a head CT without contrast after clinical stabilization due to the rapidity of the test and its ability to demonstrate common causes of acute status change, such as hemorrhage. Its most useful feature is demonstrating hydrocephalus, which may require emergent surgical action.[27] Depending on the tumor location, CT findings consistent with hydrocephalus may include enlargement of the temporal horns, triventricular or tetraventricular enlargement, and hypodensities around the frontal horns suggesting transependymal flow of CSF.[32][33]

Other CT findings include hyperdensity within the ventricular system for intraventricular lesions such as central neurocytoma and hypo- or iso-density in the brain parenchyma representing intraparenchymal lesions.[34][35] The head CT may also show calcification, but this is likely present in less than half of all neuronal and glioneuronal brain tumors. Approximately 10% of DNET and 35 to 50% of ganglioglioma demonstrate calcifications, while other primary CNS lesions like oligodendroglioma demonstrate calcification in up to 90% of lesions.[36]

MRI

MRI is the imaging test of choice for evaluating this group of brain tumors.[36][37] Sequences should include T1—and T2-weighted images with and without gadolinium contrast. Fluid-attenuated inversion recovery (FLAIR) imaging for tumor characterization and edema, susceptibility-weighted imaging (SWI) for hemorrhage and calcification, diffusion-weighted imaging (DWI) for an assessment of cellularity, and perfusion-weighted imaging (PWI) for an assessment of angiogenesis should be included as part of a standard brain tumor imaging protocol when a primary CNS tumor is suspected.

Other advanced MRI techniques, such as MR spectroscopy (MRS), diffusion tensor imaging (DTI), and functional MRI (fMRI), can also be useful. Table 2 demonstrates the most common MRI characteristics for each tumor. Due to the rare nature of many of these lesions, complete imaging characteristics are still being defined. Additionally, many of these lesions have heterogeneous imaging characteristics, and individual tumors may not demonstrate the standard features noted here.

Table

Table 2: MRI characteristics for individual neuronal and glioneuronal brain tumors.[4][17][37][38][39].

Most of the tumors within this group are primary intracranial lesions without dissemination or occurrence in other compartments within the CNS. However, patients with DLGNT, in particular, should undergo MRI with and without contrast of the entire neuroaxis due to its proclivity for dissemination throughout the neuroaxis. Consideration of imaging the spinal axis should also be given for other patients with focal neurological deficits or signs of myelopathy that cannot be explained by their intracranial lesion alone.

EEG

An important consideration for this group of brain tumors is electroencephalography (EEG) since they commonly present with seizures. Spot EEG may be useful in some cases, but continuous video EEG monitoring allows for better characterization of seizure semiology and assists with the localization of an epileptogenic focus. Invasive EEG monitoring with either subdural strip electrodes or depth electrodes can also be considered in patients with seizures that cannot be localized to the region of the tumor with noninvasive recording techniques. The specific histologic characteristics of an individual tumor may affect EEG characteristics. Tumors with mostly neuronal histology often demonstrate continuous spiking.[40] However, there are limited data regarding specific EEG characteristics for these tumors.

WADA Testing

Many LEATs are in locations where surgical resection may compromise language function. WADA testing is typically employed in these patients before resection to identify language dominance and assist with surgical planning.[41] fMRI has also been used for this purpose, but it may not be as accurate as WADA testing, which remains the gold standard for determining language dominance.[42]

Interprofessional Discussion

LEAT patients should be discussed in interprofessional epilepsy conferences involving neurosurgeons, epilepsy neurologists, neuroradiologists, and neuropathologists to make appropriate diagnostic and treatment plans for these often-complicated patients. Furthermore, these patients and others with tumors that are identified for another reason should be discussed at an interprofessional tumor board conference consisting of neurosurgeons, neurologists, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists to assist with appropriate diagnostic and treatment planning.

Treatment / Management

Observation

Asymptomatic or minimally symptomatic lesions identified on imaging for another reason can be reasonably followed with serial examination and neurological imaging due to the primarily low-grade nature of this group of tumors. Changes to the radiological characteristics of the tumor or the development of new neurological symptoms should prompt discussion at interprofessional conferences to consider intervention.

Medical Treatment for Seizures

Medical treatment for this group of tumors chiefly encompasses the use of anti-epileptic medications for LEATs. The specific agents used are variable, and typically, various agents are trialed. However, these tumors are often refractory to maximal medical therapy and typically require surgical intervention.[19]

Surgical Treatment

Surgical resection is the treatment of choice for symptomatic neuronal and glioneuronal tumors.[43] Patients who present with acute obstructive hydrocephalus require emergent surgery to prevent permanent neurological injury and death. However, that clinical scenario is unusual for this group, and most others can typically be scheduled on an outpatient basis after the decision for the need for surgical intervention has been reached in interprofessional conferences. The specifics of the intervention are highly dependent on the tumor's location. This typically involves a craniotomy with the goal of gross total tumor resection. However, some data suggest that a small residual tumor may still result in sufficient resection in the case of LEATs.[43]

Gross total resection for higher-grade lesions appears to be more important. A higher extent of resection (EOR) improves survival in patients with anaplastic ganglioglioma, similar to data from other high-grade CNS lesions such as glioblastoma.[44][45] The increasing EOR in central neurocytoma has also demonstrated a survival benefit.[46] Intraventricular lesions within this group have historically been treated with standard craniotomy and tumor resection, but modern minimally invasive surgical techniques using tubular retractor systems are beginning to emerge.[47][48]

These may help reduce some of the morbidity related to intraventricular surgery for large tumors. Laser interstitial thermal therapy (LITT) is another emerging minimally invasive surgical strategy for intracranial lesions that has been applied to brain tumors and epilepsy surgery.[49] This technique utilizes light energy to cause a thermal reaction within the target tissue, resulting in lesionectomy. Its application to neuronal and glioneuronal tumors, in particular, is limited at this time. However, it may emerge as an alternative to formal surgical resection for tumors in deep-seated and eloquent tissues.

Radiation Therapy

The role of radiation is somewhat limited for this group of tumors since most are WHO grade I. However, higher-grade lesions including anaplastic ganglioglioma, liponeurocytoma, and some central/extraventricular neurocytoma may require adjuvant radiation therapy. Radiation is most commonly employed for anaplastic ganglioglioma, although it is not employed in all cases.[50][51] 

In cases of gross total resection for anaplastic ganglioglioma, adjuvant radiation therapy alone may be considered, but clinicians should consider adjuvant chemoradiation therapy in cases of subtotal resection.[52] The use of adjuvant radiation therapy for central and extraventricular neurocytoma is also common and appears to improve survival, especially in cases of subtotal resection or tumor recurrence.[53][54][55]

Liponeurocytoma may also be treated with postoperative radiation. In case reports and small case series, patients who underwent subtotal resection or recurrent liponeurocytoma have been successfully treated with adjuvant radiotherapy.[56][57][58] Further study, ideally with randomized controlled clinical trials, is necessary to define the exact role of radiation therapy for this group of tumors as a whole, but this may be difficult due to the rare nature of many of these tumors.

Chemo- and Immunotherapy

Chemo- and immuno-therapies are typically reserved for grade 2 and 3 tumors in a fashion similar to radiation therapy. Immunotherapies targeting BRAF are emerging as adjuvant therapy for use in anaplastic ganglioglioma.[44][59][60] Examples of BRAF inhibitors include vemurafenib, dabrafenib, and encorafenib. The use of chemotherapy in central neurocytoma is variable and typically reserved for patients with recurrent tumors.[61]

Agents such as vincristine, cisplatin, etoposide, carboplatin, cyclophosphamide, and lomustine have all been documented in case reports and small cases series for use in central neurocytoma.[62] However, temozolomide, an alkylating agent available in oral and intravenous forms that is a common agent for central nervous system malignancies, has recently been favored. Treatment using chemo-or immuno-therapies for liponeurocytoma is not well documented.

Differential Diagnosis

The differential diagnosis for neuronal and glioneuronal brain tumors is broad due to their heterogeneous nature. Other primary central nervous system tumors, especially low-grade ones, may appear similar. 

• Diffuse astrocytoma
• Pilomyxoid astrocytoma
• Pleomorphic xanthoastrocytoma
• Pilocytic astrocytoma
• Oligodendroglioma
• Lymphoma
• Ependymoma
• Intraventricular tumors for central neurocytoma: Subependymal giant cell astrocytoma (SEGA); meningioma; choroid plexus papilloma or carcinoma; metastasis
• Dural-based tumors for DIG/DIA: Meningioma; dural-based metastases
• Cerebritis

Prognosis

Most data regarding outcomes for this group of tumors are related to ganglioglioma and DNET since they are the most common tumors within the group. Seizure outcomes after surgical intervention are of particular interest since seizures are the most common presenting symptom of these tumors. Mehrotra et al reviewed seizure outcomes for a series of 26 patients with seizures related to neuronal/glioneuronal brain tumors.[63] 

Favorable prognostic factors for postoperative improvement included earlier diagnosis, younger patient age, and focal partial seizure semiology. Early operative intervention was associated with the best long-term seizure outcomes. The extent of resection may also play an essential role in creating seizure freedom with surgery. A comprehensive review of the literature, including 1181 patients undergoing tumor resection with the intent of seizure control, demonstrated that 79% of patients who underwent a gross total tumor resection were seizure-free compared to only 43% of patients who underwent subtotal resection.[64]

Furthermore, patients with gross total resection plus resection of some surrounding tissue experienced 87% postoperative seizure freedom, which suggests that it may be important to respect surrounding dysplastic tissue during tumor resection. Similar findings have been demonstrated in children with epilepsy related to neuronal/glioneuronal brain tumors.[65] Significantly, shorter seizure duration is associated with improved cognitive outcomes in children, so prompt diagnosis and management in children with these brain tumors are of the utmost importance.

A specific outcome measure important for central neurocytoma is the need for long-term management of hydrocephalus with CSF shunting. The gross total resection of these tumors is related to lower ventricular shunting rates.[66]

Anaplastic ganglioglioma carries the worst prognosis of any tumor within this group. An analysis of available cases in the literature suggested a poor overall survival with the median at 29 months despite maximal therapy.[52]

Generating accurate prognoses for many of the other tumors in this group is somewhat difficult due to their rare nature. However, most appear relatively benign on histological and molecular characterization and are given low WHO grades, which suggests a favorable long-term survival. The main concern is the ability to control symptoms related to the tumors, often via surgical intervention, as discussed.

Complications

Complications related to neuronal and glioneuronal brain tumors are variable based on different treatment modalities. Adverse effects from anti-epileptic medications are common and include irritability, dizziness, drowsiness, blurred vision, difficulty with coordination, generalized fatigue, and weight gain.[67]

More serious side effects are also possible, including severe skin reactions and congenital disabilities in children if taken during pregnancy. Other complications are related to surgical intervention, including infection, intracranial and extracranial bleeding, postoperative hydrocephalus, new neurological deficit, lack of seizure control, injury to structures surrounding the tumor such as cranial nerves or blood vessels, cerebral edema and brain swelling, and death.

Consultations

Patients with a neuronal or glioneuronal brain tumor require interprofessional discussion. Patients with LEATs require consultation with neurosurgeons, epilepsy neurologists, neuroradiologists, and occasionally medical oncologists, radiation oncologists, and neuropathologists. These consultations often occur in the form of an interprofessional epilepsy conference. These and other patients with neuronal and glioneuronal brain tumors may also be discussed at an interprofessional tumor board conference, including neurosurgeons, neurologists, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists.

Deterrence and Patient Education

Patients with tumor-related epilepsy should be educated regarding seizure precautions and avoidance of secondary injury that may occur during a seizure. Family members should also be educated in recognizing seizure activity and the necessary actions to take when a seizure occurs. Patients with brain tumors should notify their provider of any new neurological symptoms, potentially representing changes to the tumor.

Enhancing Healthcare Team Outcomes

Neuronal and glioneuronal brain tumors are a heterogeneous group of tumors, so their presentations and management are variable. Therefore, effective evaluation and treatment require interprofessional input, which typically occurs in the form of epilepsy or tumor board conferences. Epilepsy evaluation requires the coordinated efforts of technicians, nurses, advanced practice providers, and physicians to appropriately identify seizure foci and ensure accurate and effective treatment for patients.

Emergency medical personnel must recognize acute neurological status changes to expedite emergency evaluation and medical or surgical responses, which helps minimize morbidity and mortality related to brain tumors. The inpatient care of postoperative brain tumor patients is complicated and requires the coordinated care of therapists, nurses, advanced practice providers, physicians, and other healthcare team members.

Specialty training regarding neurological evaluation is of utmost importance so that patient status changes are promptly recognized, and action can be taken. Therefore, increasing the awareness of these tumors among various healthcare providers helps facilitate early recognition and the effective care of these patients.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 02;23(8):1231-1251. [PMC free article: PMC8328013] [PubMed: 34185076]

2.

Shin JH, Lee HK, Khang SK, Kim DW, Jeong AK, Ahn KJ, Choi CG, Suh DC. Neuronal tumors of the central nervous system: radiologic findings and pathologic correlation. Radiographics. 2002 Sep-Oct;22(5):1177-89. [PubMed: 12235346]

3.

Giulioni M, Rubboli G, Marucci G, Martinoni M, Marliani AF, Bartiromo F, Calbucci F. Focal epilepsies associated with glioneuronal tumors: review article. Panminerva Med. 2013 Jun;55(2):225-38. [PubMed: 23676963]

4.

Abdel Razek AAK, Elsebaie NA, Zamora C, Castillo M. Imaging of Neuronal and Mixed Glioneuronal Tumors. J Comput Assist Tomogr. 2020 May/Jun;44(3):356-369. [PubMed: 32217897]

5.

Srinivasa K, Cross KA, Dahiya S. BRAF Alteration in Central and Peripheral Nervous System Tumors. Front Oncol. 2020;10:574974. [PMC free article: PMC7523461] [PubMed: 33042847]

6.

Krauze AV. Glioneuronal Tumors: Insights into a Rare Tumor Entity. In: Debinski W, editor. Gliomas [Internet]. Exon Publications; Brisbane (AU): Apr 30, 2021. [PubMed: 34038055]

7.

Choi E, Kim SI, Won JK, Chung CK, Kim SK, Choi SH, Choi S, Han B, Ahn B, Im SW, Park SH. Clinicopathological and molecular analysis of multinodular and vacuolating neuronal tumors of the cerebrum. Hum Pathol. 2019 Apr;86:203-212. [PubMed: 30550736]

8.

Stone TJ, Keeley A, Virasami A, Harkness W, Tisdall M, Izquierdo Delgado E, Gutteridge A, Brooks T, Kristiansen M, Chalker J, Wilkhu L, Mifsud W, Apps J, Thom M, Hubank M, Forshew T, Cross JH, Hargrave D, Ham J, Jacques TS. Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. Acta Neuropathol. 2018 Jan;135(1):115-129. [PMC free article: PMC5756244] [PubMed: 29058119]

9.

Métais A, Appay R, Pagès M, Gallardo C, Silva K, Siegfried A, Perbet R, Maurage CA, Scavarda D, Fina F, Uro-Coste E, Riffaud L, Colin C, Figarella-Branger D., contributors of the Biopathology RENOCLIP-LOC network. Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges. Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12769. [PubMed: 34551121]

10.

Slegers RJ, Blumcke I. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta Neuropathol Commun. 2020 Mar 09;8(1):27. [PMC free article: PMC7063704] [PubMed: 32151273]

11.

Bale TA. FGFR- gene family alterations in low-grade neuroepithelial tumors. Acta Neuropathol Commun. 2020 Feb 21;8(1):21. [PMC free article: PMC7035775] [PubMed: 32085805]

12.

Sekar A, Rudrappa S, Gopal S, Ghosal N, Rai A. Rosette-Forming Glioneuronal Tumor in Opticochiasmatic Region-Novel Entity in New Location. World Neurosurg. 2019 May;125:253-256. [PubMed: 30790744]

13.

Zamora C, Castillo M. From Dysembryoplastic Neuroepithelial Tumors to Myxoid Glioneuronal Tumors, a New Entity. AJNR Am J Neuroradiol. 2021 Nov;42(11):E77-E78. [PMC free article: PMC8583259] [PubMed: 34531194]

14.

Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol. 2020 May;30(3):479-494. [PMC free article: PMC7780370] [PubMed: 31609499]

15.

Nagaishi M, Nobusawa S, Matsumura N, Kono F, Ishiuchi S, Abe T, Ebato M, Wang Y, Hyodo A, Yokoo H, Nakazato Y. SLC44A1-PRKCA fusion in papillary and rosette-forming glioneuronal tumors. J Clin Neurosci. 2016 Jan;23:73-75. [PubMed: 26260115]

16.

Pages M, Lacroix L, Tauziede-Espariat A, Castel D, Daudigeos-Dubus E, Ridola V, Gilles S, Fina F, Andreiuolo F, Polivka M, Lechapt-Zalcman E, Puget S, Boddaert N, Liu XQ, Bridge JA, Grill J, Chretien F, Varlet P. Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta Neuropathol Commun. 2015 Dec 15;3:85. [PMC free article: PMC4681033] [PubMed: 26671581]

17.

Dragoo DD, Taher A, Wong VK, Elsaiey A, Consul N, Mahmoud HS, Mujtaba B, Stanietzky N, Elsayes KM. PTEN Hamartoma Tumor Syndrome/Cowden Syndrome: Genomics, Oncogenesis, and Imaging Review for Associated Lesions and Malignancy. Cancers (Basel). 2021 Jun 22;13(13) [PMC free article: PMC8268822] [PubMed: 34206559]

18.

Poyuran R, Mahadevan A, Mhatre R, Arimappamagan A, Sinha S, Bharath RD, Rao MB, Saini J, Raghavendra K, Mundlamuri RC, Sadashiva N, Rajeswaran J, Satishchandra P, Chandramouli BA, Shankar SK. Neuropathological spectrum of drug resistant epilepsy: 15-years-experience from a tertiary care centre. J Clin Neurosci. 2021 Sep;91:226-236. [PubMed: 34373032]

19.

Giulioni M, Marucci G, Martinoni M, Marliani AF, Toni F, Bartiromo F, Volpi L, Riguzzi P, Bisulli F, Naldi I, Michelucci R, Baruzzi A, Tinuper P, Rubboli G. Epilepsy associated tumors: Review article. World J Clin Cases. 2014 Nov 16;2(11):623-41. [PMC free article: PMC4233414] [PubMed: 25405186]

20.

Blümcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ, Battaglia G, Becker A, Cepeda C, Cendes F, Colombo N, Crino P, Cross JH, Delalande O, Dubeau F, Duncan J, Guerrini R, Kahane P, Mathern G, Najm I, Ozkara C, Raybaud C, Represa A, Roper SN, Salamon N, Schulze-Bonhage A, Tassi L, Vezzani A, Spreafico R. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011 Jan;52(1):158-74. [PMC free article: PMC3058866] [PubMed: 21219302]

21.

Barba C, Coras R, Giordano F, Buccoliero AM, Genitori L, Blümcke I, Guerrini R. Intrinsic epileptogenicity of gangliogliomas may be independent from co-occurring focal cortical dysplasia. Epilepsy Res. 2011 Nov;97(1-2):208-13. [PubMed: 21831599]

22.

Chassoux F, Landré E, Mellerio C, Laschet J, Devaux B, Daumas-Duport C. Dysembryoplastic neuroepithelial tumors: epileptogenicity related to histologic subtypes. Clin Neurophysiol. 2013 Jun;124(6):1068-78. [PubMed: 23276492]

23.

Wolf HK, Birkholz T, Wellmer J, Blümcke I, Pietsch T, Wiestler OD. Neurochemical profile of glioneuronal lesions from patients with pharmacoresistant focal epilepsies. J Neuropathol Exp Neurol. 1995 Sep;54(5):689-97. [PubMed: 7666058]

24.

Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA, Troost D. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol. 2001 Jun;27(3):223-37. [PubMed: 11489142]

25.

Fassunke J, Majores M, Tresch A, Niehusmann P, Grote A, Schoch S, Becker AJ. Array analysis of epilepsy-associated gangliogliomas reveals expression patterns related to aberrant development of neuronal precursors. Brain. 2008 Nov;131(Pt 11):3034-50. [PubMed: 18819986]

26.

Samadani U, Judkins AR, Akpalu A, Aronica E, Crino PB. Differential cellular gene expression in ganglioglioma. Epilepsia. 2007 Apr;48(4):646-53. [PubMed: 17437409]

27.

Cheng CH, Liu CL, Chen CC, Lin SZ, Cho DY. Single-port endoscopic removal of intraventricular central neurocytoma. J Clin Neurosci. 2010 Nov;17(11):1417-20. [PubMed: 20655233]

28.

Smith TW, Nikulasson S, De Girolami U, De Gennaro LJ. Immunohistochemistry of synapsin I and synaptophysin in human nervous system and neuroendocrine tumors. Applications in diagnostic neuro-oncology. Clin Neuropathol. 1993 Nov-Dec;12(6):335-42. [PubMed: 8287627]

29.

Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125-43. [PubMed: 26530364]

30.

Puzyrenko A, Cochran E, Giorgadze T, Nomani L. Papillary glioneuronal tumors: Distinctive cytological characteristics and cyto-histologic correlation. Ann Diagn Pathol. 2021 Aug;53:151757. [PubMed: 33991783]

31.

Abongwa C, Cotter J, Tamrazi B, Dhall G, Davidson T, Margol A. Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature. Pediatr Hematol Oncol. 2020 Apr;37(3):248-258. [PubMed: 31951480]

32.

Verbančič T, Ravnik J, Kavalar R. Rosette-forming glioneuronal tumor of the fourth ventricle; A case report and review of the literature. Clin Case Rep. 2021 Jun;9(6):e04355. [PMC free article: PMC8369514] [PubMed: 34429970]

33.

Sáez-Alegre M, Saceda Gutiérrez JM, Utrilla Contreras C, Aracil Santos FJ, García-Feijoo P, Carceller Benito F. Diffuse leptomeningeal glioneuronal tumour: where to biopsy? Case report and literature review. Childs Nerv Syst. 2021 Jul;37(7):2405-2408. [PubMed: 33128604]

34.

Zhang D, Wen L, Henning TD, Feng XY, Zhang YL, Zou LG, Zhang ZG. Central neurocytoma: clinical, pathological and neuroradiological findings. Clin Radiol. 2006 Apr;61(4):348-57. [PubMed: 16546465]

35.

Ramsahye H, He H, Feng X, Li S, Xiong J. Central neurocytoma: radiological and clinico-pathological findings in 18 patients and one additional MRS case. J Neuroradiol. 2013 May;40(2):101-11. [PubMed: 23410895]

36.

Luzzi S, Elia A, Del Maestro M, Elbabaa SK, Carnevale S, Guerrini F, Caulo M, Morbini P, Galzio R. Dysembryoplastic Neuroepithelial Tumors: What You Need to Know. World Neurosurg. 2019 Jul;127:255-265. [PubMed: 30981794]

37.

Joo G, Doumanian J. Radiographic Findings of Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease) in a Woman with Cowden Syndrome: A Case Study and Literature Review. J Radiol Case Rep. 2020 Mar;14(3):1-6. [PMC free article: PMC7535995] [PubMed: 33082915]

38.

Thomas B, Krishnamoorthy T, Radhakrishnan VV, Kesavadas C. Advanced MR imaging in Lhermitte-Duclos disease: moving closer to pathology and pathophysiology. Neuroradiology. 2007 Sep;49(9):733-8. [PubMed: 17549467]

39.

Gaballo A, Palma M, Dicuonzo F, Carella A. Lhermitte-Duclos disease: MR diffusion and spectroscopy. Radiol Med. 2005 Oct;110(4):378-84. [PubMed: 16292245]

40.

Schramm J, Aliashkevich AF. Surgery for temporal mediobasal tumors: experience based on a series of 235 patients. Neurosurgery. 2008 Jun;62(6 Suppl 3):1272-82. [PubMed: 18695547]

41.

Vivas AC, Reintjes S, Shimony N, Vale FL. Surgery of the amygdala and uncus: a case series of glioneuronal tumors. Acta Neurochir (Wien). 2020 Apr;162(4):795-801. [PMC free article: PMC7066292] [PubMed: 31997072]

42.

Ishikawa T, Muragaki Y, Maruyama T, Abe K, Kawamata T. Roles of the Wada Test and Functional Magnetic Resonance Imaging in Identifying the Language-dominant Hemisphere among Patients with Gliomas Located near Speech Areas. Neurol Med Chir (Tokyo). 2017 Jan 15;57(1):28-34. [PMC free article: PMC5243162] [PubMed: 27980284]

43.

Zaghloul KA, Schramm J. Surgical management of glioneuronal tumors with drug-resistant epilepsy. Acta Neurochir (Wien). 2011 Aug;153(8):1551-9. [PubMed: 21603887]

44.

Klimko A, Dandes M, Paslaru F, Giovani A. Primary Anaplastic Ganglioglioma of the Temporal Lobe With Brainstem Involvement: A Case Report and Literature Review. Cureus. 2020 Dec 13;12(12):e12060. [PMC free article: PMC7802110] [PubMed: 33447489]

45.

Haydon DH, Dahiya S, Smyth MD, Limbrick DD, Leonard JR. Greater extent of resection improves ganglioglioma recurrence-free survival in children: a volumetric analysis. Neurosurgery. 2014 Jul;75(1):37-42. [PubMed: 24625425]

46.

Vasiljevic A, François P, Loundou A, Fèvre-Montange M, Jouvet A, Roche PH, Figarella-Branger D. Prognostic factors in central neurocytomas: a multicenter study of 71 cases. Am J Surg Pathol. 2012 Feb;36(2):220-7. [PubMed: 22251941]

47.

Goel A, Vutha R, Shah A, Singh K, Goel N, Shenoy A, Rai S, Dandpat S. Large lateral intraventricular tumors - Outcome of radical surgery. J Clin Neurosci. 2021 Jun;88:205-212. [PubMed: 33992185]

48.

Okasha M, Ineson G, Pesic-Smith J, Surash S. Transcortical Approach to Deep-Seated Intraventricular and Intra-axial Tumors Using a Tubular Retractor System: A Technical Note and Review of the Literature. J Neurol Surg A Cent Eur Neurosurg. 2021 May;82(3):270-277. [PubMed: 33321519]

49.

Salem U, Kumar VA, Madewell JE, Schomer DF, de Almeida Bastos DC, Zinn PO, Weinberg JS, Rao G, Prabhu SS, Colen RR. Neurosurgical applications of MRI guided laser interstitial thermal therapy (LITT). Cancer Imaging. 2019 Oct 15;19(1):65. [PMC free article: PMC6792239] [PubMed: 31615562]

50.

Selvanathan SK, Hammouche S, Salminen HJ, Jenkinson MD. Outcome and prognostic features in anaplastic ganglioglioma: analysis of cases from the SEER database. J Neurooncol. 2011 Dec;105(3):539-45. [PubMed: 21626070]

51.

Terrier LM, Bauchet L, Rigau V, Amelot A, Zouaoui S, Filipiak I, Caille A, Almairac F, Aubriot-Lorton MH, Bergemer-Fouquet AM, Bord E, Cornu P, Czorny A, Dam Hieu P, Debono B, Delisle MB, Emery E, Farah W, Gauchotte G, Godfraind C, Guyotat J, Irthum B, Janot K, Le Reste PJ, Liguoro D, Loiseau H, Lot G, Lubrano V, Mandonnet E, Menei P, Metellus P, Milin S, Muckenstrum B, Roche PH, Rousseau A, Uro-Coste E, Vital A, Voirin J, Wager M, Zanello M, François P, Velut S, Varlet P, Figarella-Branger D, Pallud J, Zemmoura I., Club de Neuro-Oncologie of the Société Française de Neurochirurgie. Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro Oncol. 2017 May 01;19(5):678-688. [PMC free article: PMC5464461] [PubMed: 28453747]

52.

Mallick S, Benson R, Melgandi W, Giridhar P, Rath GK. Impact of surgery, adjuvant treatment, and other prognostic factors in the management of anaplastic ganglioglioma. Childs Nerv Syst. 2018 Jun;34(6):1207-1213. [PubMed: 29594461]

53.

Samhouri L, Meheissen MAM, Ibrahimi AKH, Al-Mousa A, Zeineddin M, Elkerm Y, Hassanein ZMA, Ismail AA, Elmansy H, Al-Hanaqta MM, Al-Azzam OA, Elsaid AA, Kittel C, Micke O, Stummer W, Elsayad K, Eich HT. Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis. Cancers (Basel). 2021 Aug 26;13(17) [PMC free article: PMC8430823] [PubMed: 34503124]

54.

Mallick S, Benson R, Rath GK. Patterns of care and survival outcomes in patients with an extraventricular neurocytoma: An individual patient data analysis of 201 cases. Neurol India. 2018 Mar-Apr;66(2):362-367. [PubMed: 29547155]

55.

Chen YD, Li WB, Feng J, Qiu XG. Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma. Radiat Oncol. 2014 Nov 06;9:242. [PMC free article: PMC4236432] [PubMed: 25373333]

56.

Gembruch O, Junker A, Mönninghoff C, Ahmadipour Y, Darkwah Oppong M, Sure U, El Hindy N, Lemonas E. Liponeurocytoma: Systematic Review of a Rare Entity. World Neurosurg. 2018 Dec;120:214-233. [PubMed: 30205225]

57.

Wang KE, Ni M, Wang L, Jia G, Wu Z, Zhang L, Zhang J. Cerebellar liponeurocytoma: A case report and review of the literature. Oncol Lett. 2016 Feb;11(2):1061-1064. [PMC free article: PMC4734111] [PubMed: 26893691]

58.

Al-Umran MR, Al-Umran SR, Arab AF, Dababo MA, Alotaibi FA. Lateral ventricular liponeurocytoma: Review of literature and case illustration. Neurochirurgie. 2021 Nov;67(6):579-586. [PubMed: 33766564]

59.

Marks AM, Bindra RS, DiLuna ML, Huttner A, Jairam V, Kahle KT, Kieran MW. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatr Blood Cancer. 2018 May;65(5):e26969. [PubMed: 29380516]

60.

Kowalewski A, Durślewicz J, Zdrenka M, Grzanka D, Szylberg Ł. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. Target Oncol. 2020 Aug;15(4):531-540. [PMC free article: PMC7434793] [PubMed: 32648041]

61.

Johnson MO, Kirkpatrick JP, Patel MP, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB. The role of chemotherapy in the treatment of central neurocytoma. CNS Oncol. 2019 Nov 01;8(3):CNS41. [PMC free article: PMC6880304] [PubMed: 31686534]

62.

Buchbinder D, Danielpour M, Yong WH, Salamon N, Lasky J. Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue. J Neurooncol. 2010 May;97(3):429-37. [PMC free article: PMC2858278] [PubMed: 19924515]

63.

Mehrotra A, Singh S, Kanjilal S, Pal L, Paliwal VK, Sardhara J, Behari S. Seizure-outcome after surgery of low-grade epilepsy associated neuro-epithelial tumors. J Neurosurg Sci. 2023 Oct;67(5):591-597. [PubMed: 33320468]

64.

Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012 Apr;70(4):921-8; discussion 928. [PubMed: 21997540]

65.

Faramand AM, Barnes N, Harrison S, Gunny R, Jacques T, Tahir MZ, Varadkar SM, Cross HJ, Harkness W, Tisdall MM. Seizure and cognitive outcomes after resection of glioneuronal tumors in children. Epilepsia. 2018 Jan;59(1):170-178. [PubMed: 29178251]

66.

Soliman WS. Ventricular Central Neurocytoma: Rate of Shunting and Outcome 2 Years After Total and Subtotal Excision. Acta Neurochir Suppl. 2017;124:179-185. [PubMed: 28120072]

67.

Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012 Sep;11(9):792-802. [PubMed: 22832500]

Disclosure: Frank Mezzacappa declares no relevant financial relationships with ineligible companies.

Disclosure: William Thorell declares no relevant financial relationships with ineligible companies.